Form 8.3 - Horizon Therapeutics plc

LONDON--()-- 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

  1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Horizon Therapeutics plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

IE00BQPVQZ61

Date of dealing

23rd January 2023

  1. INTERESTS AND SHORT POSITIONS
  1. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

4,287,066

(1.874%)

38,116

(0.017%)

(2) Derivatives (other than options)

2

(0.000%)

621

(0.000%)

(3) Options and agreements to purchase/sell

75,000

(0.033%)

143,200

(0.063%)

Total

4,362,068

(1.907%)

181,937

(0.080%)

  1. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Ap20

  1. DEALINGS (Note 4)
  1. Purchases and sales

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

8,106

112.99

Purchase

38,073

113.00

Purchase

4,006

112.97

Purchase

2,984

112.98

Purchase

6,318

112.96

Purchase

5,238

112.95

Purchase

900

112.94

Purchase

874

112.93

Purchase

445

113.02

Purchase

47

113.03

Purchase

600

112.81

Purchase

10,774

113.01

Purchase

1,491

112.90

Purchase

3

113.04

Purchase

393

112.82

Purchase

490

112.86

Purchase

200

112.85

Purchase

105

112.84

Purchase

100

112.88

Purchase

100

112.83

Purchase

100

112.87

Purchase

15

112.99

Purchase

10

113.00

Purchase

48

112.97

Purchase

5

112.98

Purchase

99

112.96

Purchase

10

112.95

Sale

41

112.95

Sale

200

112.94

Sale

127

112.93

Purchase

319

112.81

Sale

7

113.01

Sale

143

112.92

Sale

200

112.97

Sale

286

112.96

Purchase

41

112.95

Purchase

3

113.03

Purchase

23,104

112.99

Purchase

30,838

113.00

Purchase

11,759

112.97

Purchase

6,102

112.98

Purchase

19,339

112.96

Purchase

7,567

112.95

Sale

147

112.95

Purchase

873

112.94

Purchase

533

112.93

Sale

2

112.93

Purchase

6,204

113.02

Sale

20

113.02

Purchase

27,708

113.03

Sale

1

113.03

Purchase

58,909

112.81

Sale

7,500

112.81

Purchase

16,808

113.01

Purchase

400

112.90

Sale

30

112.90

Purchase

7

112.86

Purchase

378

112.85

Purchase

12

112.84

Purchase

175

112.91

Purchase

14

112.88

Purchase

1,643

112.83

Purchase

591

112.92

Sale

58,800

112.81

Purchase

8,032

112.98

Sale

7,691

112.98

Sale

187

112.90

Purchase

7,500

112.81

  1. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

Equity Swap

Opening a long position

2

113.03

  1. Options transactions in respect of existing relevant securities
  1. Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Put Option

Purchasing

15,400

110.00

American

2/17/2023

 

  1. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

  1. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure

24th January 2023

Contact name

Roisin Nagle

Telephone number

+44 203 192 8746

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:

Millennium International Management LP

Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:

Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security

Product
description
e.g. call
option

Written or
purchased

Number of
securities to
which option
or derivative
relates

Exercise
price
per unit

Type
e.g.
American,
European
etc.

Expiry
date

IE00BQPVQZ61

Call Option

Written

29,100

110.00

American

2/17/2023

IE00BQPVQZ61

Call Option

Purchased

29,100

100.00

American

2/17/2023

IE00BQPVQZ61

Put Option

Purchased

1,500

90.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

3,000

110.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Written

3,000

115.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

42,500

120.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

400

115.00

American

3/17/2023

IE00BQPVQZ61

Put Option

Purchased

400

115.00

American

3/17/2023

IE00BQPVQZ61

Put Option

Purchased

2,500

110.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

106,700

110.00

American

2/17/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET
Sequence Number: 1055711
Time of Receipt (offset from UTC): 20230124T125659+0000

Contacts

Millennium Partners, L.P.

Contacts

Millennium Partners, L.P.